Cerevel Therapeutics (Nasdaq: CERE) has released encouraging findings from its pivotal Phase 3 TEMPO-3 trial for tavapadon, a unique D1/D5 receptor partial agonist investigated as a once-daily treatment for Parkinson’s disease. This trial assessed tavapadon’s efficacy, safety, and tolerability as…
A new oral vaccine for cholera has received prequalification by the World Health Organization (WHO) on 12 April. The inactivated oral vaccine Euvichol-S has a similar efficacy to existing vaccines but a simplified formulation, allowing opportunities to rapidly increase production…
Today, the joint effort of the International Coalition of Medicines Regulatory Authorities (ICMRA) and the World Health Organization (WHO) culminated in the publication of a comprehensive report detailing the outcomes of their recent workshop on COVID-19 vaccine strain updates. Conducted…
Sanofi’s frexalimab, a CD40L antibody, has displayed enduring effectiveness and favorable tolerability over almost a year in individuals with relapsing multiple sclerosis (MS). These findings will be unveiled today at the American Academy of Neurology (AAN) 2024 Annual Meeting in…
Alert Overview This alert from the World Health Organization (WHO) addresses the discovery of falsified DOW USP/EP Propylene Glycol in Pakistan. Authentic DOW USP/EP Propylene Glycol is a crucial raw material used in pharmaceutical and other manufacturing processes, meeting the…
Novartis recently shared promising findings from the Phase III APPLAUSE-IgAN study of Fabhalta® (iptacopan), a Factor B inhibitor targeting the alternative complement pathway, in patients with IgA nephropathy (IgAN). In this interim analysis, patients treated with Fabhalta experienced a significant…
Agenus Inc. (NASDAQ: AGEN), a renowned player in the realm of discovering and advancing novel immunological treatments for diverse cancers, has disclosed the latest outcomes from its Phase 1 clinical assessment of BOT/BAL combination therapy targeting patients with metastatic CRC…
Novartis has officially released the offer document for its subsidiary, Novartis BidCo AG’s, voluntary public takeover bid for all outstanding shares of MorphoSys AG, inclusive of MorphoSys American Depositary Shares (ADS), at an offer price of EUR 68.00 per share…
Pfizer Inc. (NYSE: PFE) has reported promising top-line data on the immunogenicity and safety of ABRYSVO® from its pivotal Phase 3 clinical trial MONeT (RSV IMmunizatiON Study for AdulTs at Higher Risk of Severe Illness). The trial, registered under NCT05842967,…
Allergan Aesthetics, a subsidiary of AbbVie Inc. (NYSE: ABBV), has unveiled two new additions to the SkinMedica® lineup, developed by the creators of BOTOX® Cosmetic. These groundbreaking products, the SkinMedica® Acne Clarifying Treatment and SkinMedica® Pore Purifying Gel Cleanser, mark…
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has unveiled comprehensive findings from the Phase 3 Balance study of olezarsen, its leading independent investigational medication, targeted at adults grappling with familial chylomicronemia syndrome (FCS). The study revealed that the monthly administration of olezarsen…
A joint mission led by the World Health Organization (WHO) and several other agencies visited Al-Shifa Hospital in north Gaza on April 5 to assess the damage caused by the ongoing conflict and identify necessary steps for its restoration. The…
